In Tuesday’s first-quarter 2024 financial results, Bayer reported a slight drop in sales amid its sweeping companywide ...

With Monday’s agreement, AbbVie joins the industry’s growing interest in psychedelic therapies and looks to leverage ...

Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...

Dynavax Technologies announced Tuesday that the FDA issued a Complete Response Letter in response to the company’s sBLA to ...

Cytokinetics released data Monday on aficamten, an oral small molecule inhibitor of cardiac myosin, showing it significantly ...

Results from a Phase I study presented Friday at the ASGCT 2024 annual meeting showed that despite a good safety profile, ...

An updated draft of the BIOSECURE Act introduced on Friday would give U.S. drug manufacturers additional leeway for existing ...

The FDA is looking at five big decision deadlines in the coming three weeks, including two for a CAR-T therapy and another ...

The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could ...

The major biopharma players have promised to increase their investments in France to help boost their respective global ...

Takeda on Monday said it is paying AC Immune $100 million upfront for an option on a Phase Ib/II Alzheimer’s disease ...

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central ...